Form 4: CEO Christopher Kroeger Sells MapLight Therapeutics Shares
Statement of Changes in Beneficial Ownership
CEO Christopher Kroeger sold 118,235 shares of MapLight Therapeutics under a pre-arranged Rule 10b5-1 trading plan.
Summary
- CEO Christopher Kroeger sold a total of 118,235 shares of Voting Common Stock on May 18, 2026.
- The sales were executed in two tranches: 118,037 shares at a weighted average price of $27.19 and 198 shares at a weighted average price of $28.15.
- Following these transactions, the CEO retains beneficial ownership of 1,394,094 shares.
- The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 29, 2025.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted via a pre-planned, automated trading program.
Positives
- The sale was executed under a pre-established Rule 10b5-1 plan, which is a standard mechanism for executives to sell shares without triggering insider trading concerns.
Negatives
- The sale represents a reduction in the CEO's direct equity stake in the company.
Risks
- Insider selling can sometimes be perceived negatively by the market as a signal of management's view on the company's valuation or future prospects.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Industry Context
StockSavvy.ai notes that executive stock sales under 10b5-1 plans are routine corporate governance events and generally do not reflect a change in the company's fundamental business outlook.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for executives to manage personal liquidity while maintaining compliance with SEC regulations.
Stakeholder Impact
- Shareholders should note the reduction in insider ownership, though the use of a 10b5-1 plan mitigates concerns regarding potential non-public information usage.
Next Steps
- Continued monitoring of future Form 4 filings for further insider activity.
Key Dates
| Date | Description |
|---|---|
| 2025-12-29 | Date the Rule 10b5-1 trading plan was adopted. |
| 2026-05-18 | Date of the reported stock sale transactions. |
Keywords
MapLight Therapeutics, MPLT, Insider Trading, Form 4, Christopher Kroeger, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.